TLDR

  • KALA BIO has announced the upcoming release of its inaugural commercial AI product, scheduled for launch in approximately two weeks.
  • The firm is rebranding itself as the “Palantir for biotech,” aiming to capture a share of the $180 billion healthcare AI sector.
  • The new Researgency.ai platform is designed to implement AI agents to streamline pharmaceutical and biotech operational workflows.
  • Shares of KALA experienced a 69.68% surge during Wednesday’s pre-market session, building on a 12.82% increase from the previous day.
  • Trading activity spiked to 51 million shares, significantly outpacing the three-month daily average of roughly 1.94 million.

KALA BIO shares rallied in Wednesday’s pre-market trading following the clinical-stage biotech firm’s disclosure that it intends to roll out its first commercial AI offering in about 14 days.

KALA BIO, Inc., KALA
KALA Stock Card

This news triggered a 69.68% jump in the stock price before the market opened, extending a 12.82% rise from Tuesday. Trading volume surged to over 51 million, a sharp contrast to the three-month average of approximately 1.94 million.

The company is introducing Researgency.ai, a platform engineered to deploy AI agents for pharmaceutical and biotech organizations. KALA stated its ambition to become the “Palantir for biotech,” citing Palantir’s valuation of over $250 billion as a benchmark.

KALA CEO Avi Minkowitz stated: “Our first agent ships in 14 days, and our team is fired up.”

In collaboration with the AI engineering team at Younet, KALA is developing its first custom agent, with a target delivery date in late March. The Researgency.ai platform is currently operational and accessible to enterprise users.

What the Platform Does

These AI agents are built to manage complex, high-priority drug development tasks, including clinical trial documentation, research monitoring, safety reporting, regulatory compliance, and preparations for commercial launches.

KALA claims these agents will perform these functions with greater speed, lower costs, and higher accuracy than human counterparts, all within a secure environment that adheres to pharmaceutical-grade compliance requirements.

The company referenced forecasts suggesting the global AI-in-healthcare market will surpass $180 billion by 2030. Currently, KALA holds a market capitalization of $8.3 million, with shares priced at $0.29.

Year-to-date, the stock has declined 47.21%, and it has dropped 95.78% over the last 12 months. Despite the pre-market rally on Wednesday, the stock remains near all-time lows.

Dual Strategy and Financial Pressures

KALA BIO is pursuing a two-pronged approach. It continues to maintain its biologics pipeline, which features candidates with FDA Fast Track and Orphan Drug designations based on its mesenchymal stem cell secretome technology.

This shift toward AI occurs as the company faces significant financial constraints. With a current ratio of 0.75, the firm’s short-term liabilities exceed its liquid assets.

Earlier this year, KALA reached a settlement regarding a debt dispute with Oxford Finance, paying $2 million to resolve approximately $10.6 million in outstanding loan obligations.

Additionally, the company recently ended its relationship with auditor Deloitte & Touche LLP, and a successor has not yet been announced.

KALA has not provided details regarding the pricing of the Researgency.ai platform, the specific workflow the initial agent will address, or any existing client agreements.

The company indicated that it will disclose comprehensive information about the first agent following its launch, including the specific workflow targeted and the metrics used to evaluate its performance.